IP Library Granted Patent US 11,433,043
Granted Patent B2
US 11,433,043 · App. 16/906,814 · Granted Sep 6, 2022

Compounds useful for increasing neurogenesis in neural tissue

Inventors: Mariagrazia Grilli (Novara, IT); Pier Luigi Canonico (Novara, IT); Aleardo Koverech (Rome, IT)
Assignee: ALFASIGMA S.P.A.
A61K31/225A61K31/205A61K31/21A61P9/10A61P21/02A61P25/00A61P25/14A61P25/16A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,433,043
App. No.
16/906,814
Granted
Sep 6, 2022
Kind
B2
Abstract

The invention described herein is directed to the use of acetyl L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in which said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition.

Claims (5)

1. A method for increasing neurogenesis in a patient in need thereof, said method consisting of administering to said patient in need a dose of an active agent, said active agent consisting of acetyl L-carnitine or a salt thereof, wherein said dose corresponds to 1.00 g/day to 2.00 g/day administered in a single or multiple doses, and

increasing said neurogenesis in said patient.

2. The method of claim 1 , wherein the salt of acetyl L-carnitine is selected from the group consisting of: chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate and acid tartrate, glycerophosphate, mucate, magnesium tartrate, 2-amino-ethanesulphonate, magnesium 2-amino-ethanesulphonate, methanesulphonate, choline tartrate, trichloroacetate, and trifluoroacetate.

3. The method of claim 1 , wherein the acetyl L-carnitine is administered in a dose of 1.5 g/day, in a single or multiple doses.

4. The method of claim 1 , wherein the acetyl L-carnitine is administered by oral, subcutaneous, transdermal, intraperitoneal, intramuscular, in vein, intracerebroventricular, intraparenchymal, intrathecal, intracranial, buccal, mucosal, nasal, pulmonary, rectal administration or by a liposome delivery system.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 52994 FRAME: 064. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 22, 2020
From: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE
To: ALFASIGMA S.P.A.
Reel/Frame 053590/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2020
From: GRLLI, MARIAGRAZIA; CANONICO, PIER LUIGI; KOVERECH, ALEARDO
To: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE, S.P.A.
Reel/Frame 052993/0067 →
MERGER Recorded Jun 19, 2020
From: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
To: ALFA SIGMA S.P.A.
Reel/Frame 052994/0064 →
CHANGE OF ADDRESS Recorded Jun 19, 2020
From: ALFASIGMA S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 053637/0247 →
Priority Claims (1)
EP 10166094 · Jun 16, 2010 · regional
Continuity (3)
Continuation 15159321 · May 19, 2016
Continuation 13699930
Related Publication 20200323809A1 · Oct 15, 2020